Fibroblast growth factor 23 is associated with subclinical cerebrovascular damage: The northern manhattan study

Stroke

Volumn 47, Issue 4, 2016, Pages 923-928

  Wright, Clinton B ^a,b,c,d   Shah, Nirav H ^a,e   Mendez, Armando J ^c   De Rosa, Janet T ^f   Yoshita, Mitsuhiro ^g   Elkind, Mitchell S V ^f   Sacco, Ralph L ^a,b,c,d   De Carli, Charles ^h   Rundek, Tatjana ^a,b,c   Silverberg, Shonni ^f   Dong, Chuanhui ^a,b   Wolf, Myles ⁱ  

^a UNIVERSITY OF FLORIDA   (United States)

^b Departments of Neurology   (United States)

^c Department of Public Health Sciences ^*  (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f University of Miami ^*  (United States)

^g National Hospital Organization   (Japan)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Cohort studies; Fibroblast growth factor 23; Leukoaraiosis; Magnetic resonance imaging (MRI)

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR;

AGED; ARTICLE; BRAIN INFARCTION; BRAIN SIZE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; SEX DIFFERENCE; SUBCLINICAL CEREBROVASCULAR DAMAGE; WHITE MATTER; BLOOD; BRAIN; CEREBROVASCULAR DISORDERS; CHRONIC KIDNEY FAILURE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN; CEREBROVASCULAR DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; WHITE MATTER;

EID: 84960191962     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.012379     Document Type: Article

References (35)

1. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al; HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011;22:1913-1922. doi: 10.1681/ASN.2010121224.
2. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592. doi: 10.1056/NEJMoa0706130.
3. van Venrooij NA, Pereira RC, Tintut Y, Fishbein MC, Tumber N, Demer LL, et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant. 2014;29:1525-1532. doi: 10.1093/ndt/gft523.
4. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012;60:200-207. doi: 10.1016/j. jacc.2012.03.040.
5. Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011;6:2871-2878. doi: 10.2215/CJN.02740311.
6. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC. Plasma fbroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011;161:956-962. doi: 10.1016/j. ahj.2011.02.012.
7. Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, et al. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology. 2014;82:1700-1706. doi: 10.1212/WNL.0000000000000410.
8. Panwar B, Jenny NS, Howard VJ, Wadley VG, Muntner P, Kissela BM, et al. Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke. 2015;46:322-328. doi: 10.1161/STROKEAHA.114.007489.
9. Shah NH, Dong C, Elkind MS, Sacco RL, Mendez AJ, Hudson BI, et al. Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. Arterioscler Thromb Vasc Biol. 2015;35:2048-2053. doi: 10.1161/ATVBAHA.115.305945.
10. Schilling S, Tzourio C, Dufouil C, Zhu Y, Berr C, Alpérovitch A, et al. Plasma lipids and cerebral small vessel disease. Neurology. 2014;83:1844-1852. doi: 10.1212/WNL.0000000000000980.
11. Willey JZ, Gardener H, Moon YP, Yoshita M, DeCarli C, Cheung YK, et al. Lipid profile components and subclinical cerebrovascular disease in the northern Manhattan study. Cerebrovasc Dis. 2014;37:423-430. doi: 10.1159/000362920.
12. Marcus J, Gardener H, Rundek T, Elkind MS, Sacco RL, Decarli C, et al. Baseline and longitudinal increases in diastolic blood pressure are associated with greater white matter hyperintensity volume: the northern Manhattan study. Stroke. 2011;42:2639-2641. doi: 10.1161/STROKEAHA.111.617571.
13. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D'Agostino RB, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke. 2004;35:1857-1861. doi: 10.1161/01. STR.0000135226.53499.85.
14. Rost NS, Rahman RM, Biff A, Smith EE, Kanakis A, Fitzpatrick K, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology. 2010;75:1670-1677. doi: 10.1212/WNL.0b013e3181fc279a.
15. Windham BG, Griswold ME, Shibata D, Penman A, Catellier DJ, Mosley TH Jr. Covert neurological symptoms associated with silent infarcts from midlife to older age: the Atherosclerosis Risk in Communities study. Stroke. 2012;43:1218-1223. doi: 10.1161/STROKEAHA.111.643379.
16. Prabhakaran S, Wright CB, Yoshita M, Delapaz R, Brown T, DeCarli C, et al. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology. 2008;70:425-430. doi: 10.1212/01.wnl.0000277521.66947.e5.
17. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672-2713. doi: 10.1161/STR.0b013e3182299496.
18. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke. 2005;36:1207-1211. doi: 10.1161/01.STR.0000165923.02318.22.
19. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729-2735.
20. DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging. 2005;26:491-510. doi: 10.1016/j.neurobiolaging.2004.05.004.
21. Levey A, Kusek J, Beck G. A simplifed equation to predict glomeru-lar fltration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000;11:155A.
22. Garimella PS, Ix JH, Katz R, Chonchol MB, Kestenbaum BR, de Boer IH, et al. Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study. Atherosclerosis. 2014;233:91-96. doi: 10.1016/j. atherosclerosis.2013.12.015.
23. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fbro-blast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385-390. doi: 10.1016/j. atherosclerosis.2009.01.001.
24. Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail. 2014;7:409-417. doi: 10.1161/CIRCHEARTFAILURE.113.000952.
25. Voigt M, Fischer DC, Rimpau M, Schareck W, Haffner D. Fibroblast growth factor (FGF)-23 and fetuin-A in calcifed carotid atheroma. Histopathology. 2010;56:775-788. doi: 10.1111/j.1365-2559.2010.03547.x.
26. Nakayama M, Kaizu Y, Nagata M, Ura Y, Ikeda H, Shimamoto S, et al. Fibroblast growth factor 23 is associated with carotid artery calcifcation in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol. 2013;14:22. doi: 10.1186/1471-2369-14-22.
27. Khatri M, Wright CB, Nickolas TL, Yoshita M, Paik MC, Kranwinkel G, et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke. 2007;38:3121-3126. doi: 10.1161/STROKEAHA.107.493593.
28. Olauson H, Qureshi AR, Miyamoto T, Barany P, Heimburger O, Lindholm B, et al. Relation between serum fbroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant. 2010;25:3033-3038. doi: 10.1093/ndt/gfq191.
29. Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fbroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis. 2011;58:737-745. doi: 10.1053/j.ajkd.2011.06.011.
30. Cannata-Andía JB, Carrillo-López N, Naves-Díaz M. Estrogens and bone disease in chronic kidney disease: role of FGF23. Curr Opin Nephrol Hypertens. 2010;19:354-358. doi: 10.1097/MNH.0b013e328338f508.
31. Zhang D, Maalouf NM, Adams-Huet B, Moe OW, Sakhaee K. Effects of sex and postmenopausal estrogen use on serum phosphorus levels: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003-2006. Am J Kidney Dis. 2014;63:198-205. doi: 10.1053/j.ajkd.2013.07.012.
32. Takao M, Koto A, Tanahashi N, Fukuuchi Y, Takagi M, Morinaga S. Pathologic fndings of silent, small hyperintense foci in the basal ganglia and thalamus on MRI. Neurology. 1999;52:666-668.
33. Takao M, Koto A, Tanahashi N, Fukuuchi Y, Takagi M, Morinaga S. Pathologic fndings of silent hyperintense white matter lesions on MRI. J Neurol Sci. 1999;167:127-131.
34. Kang DW, Chalela JA, Ezzeddine MA, Warach S. Association of isch-emic lesion patterns on early diffusion-weighted imaging with TOAST stroke subtypes. Arch Neurol. 2003;60:1730-1734. doi: 10.1001/archneur.60.12.1730.
35. Debette S, Wolf PA, Beiser A, Au R, Himali JJ, Pikula A, et al. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology. 2009;73:2071-2078. doi: 10.1212/WNL.0b013e3181c67833.